Abstract

To the Editors: Animal models play a key role in helping us determine the pathogenesis of diseases, and are vital for the discovery of new therapies and the improvement of existing medication. To do this, the model(s) need to closely mimic the clinical features and, where possible, be relevant to the disease in humans. Classically, the innocuous antigen ovalbumin (OVA) has been used to induce an allergic reaction in animals, and whilst it is possible to reproduce many of the features of the asthmatic lung, i.e. specific immunoglobulin (Ig)E levels, T-helper cell (Th)2-associated eosinophilic inflammation, early and late asthmatic responses (EAR and LAR, respectively), and airway hyperresponsiveness and associated tissue remodelling, researchers began to question the clinical relevance of using OVA as a model allergen 1. In addition, it was commonly felt that the need for systemic delivery of OVA, with an adjuvant such as aluminium hydroxide, did not …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.